Brand-name drug
Descovy price, strengths & recalls
Brand of emtricitabine / tenofovir alafenamide (generic)
Pharmacies pay $2,248.24 for 30 tablets of Descovy 200 mg / 25 mg tablet this week, and from $2,245.62 to $2,248.24 across its 2 priced strengths and forms. Its official label last changed on July 29, 2026.
Brand- Fair cash price
- $2,595.98
- Strengths
- 2
- Makers
- 1
- Updated
- Nov 11
Descovy price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 120 mg / 15 mg tablet Brand | $74.85 | $2,245.62 / 30 tablets |
| 200 mg / 25 mg tablet Brand | $74.94 | $2,248.24 / 30 tablets |
Descovy vs generic emtricitabine / tenofovir alafenamide
There is no generic version of Descovy on the market yet. Its last listed patent or exclusivity runs to June 29, 2036 - generics often follow, though court cases and settlements can move the date either way.
GenericEmtricitabine / tenofovir alafenamide pricesSupply status: shortages & recalls
What people paid for Descovy
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use DESCOVY safely and effectively. See full prescribing information for DESCOVY. DESCOVY® (emtricitabine and tenofovir alafenamide) tablets, for oral use Initial U.S. Approval: 2015
WARNING: POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE OF DESCOVY FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION
Severe acute exacerbations of hepatitis B (HBV) have been reported in individuals with HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF) and may occur with discontinuation of DESCOVY.
Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in individuals with HBV who discontinue DESCOVY. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1)].
DESCOVY used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with use of FTC/TDF for HIV-1 PrEP following undetected acute HIV-1 infection. Do not initiate DESCOVY for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection are present unless negative infection status is confirmed [see Warnings and Precautions (5.2)].
WARNING: POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE OF DESCOVY FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION
See full prescribing information for complete boxed warning.
Severe acute exacerbations of hepatitis B (HBV) have been reported in individuals with HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of DESCOVY. Hepatic function should be monitored closely in these individuals. If appropriate, anti-hepatitis B therapy may be warranted. (5.1)
DESCOVY used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with use of FTC/TDF for HIV-1 PrEP following undetected acute HIV-1 infection. Do not initiate DESCOVY for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection are present unless negative infection status is confirmed. (5.2)
Recent major changes (as listed on the label)
Indications and Usage (1.1) | 06/2025 |
Dosage and Administration, Recommended Dosage for Treatment of HIV-1 Infection in Pediatric Patients Weighing at Least 14 kg to Less than 35 kg (2.4) | 06/2025 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA208215 · Gilead Sciences Inc
- First approved
- April 4, 2016 (10 years ago)
- Latest approved change
- June 20, 2025
- Approved label
- PDF, Jun 23, 2025
- Generic makers
- None on the market
- Last patent listed
- June 29, 2036
- Exclusivity ends
- June 20, 2032
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Descovy questions
How much does descovy cost without insurance?
Pharmacies pay about $2,248.24 for 30 tablets of descovy 200 mg / 25 mg tablet ($74.94 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $2,595.98. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Descovy?
Yes: emtricitabine / tenofovir alafenamide. Compare emtricitabine / tenofovir alafenamide prices.
Is descovy in shortage?
No shortage is reported for descovy right now. We check the national shortage list every day.
Has descovy been recalled?
No recalls are on record for descovy.
When did the descovy label last change?
The official label was last updated on July 29, 2026 (version 13). See what changed.
Talk about descovy
No comments yet. Questions, tips, what worked for you - start the conversation.